SCHEMBL9923246

SCHEMBL9923246

Cc1c(O)c2ccccc2c(=O)n1-c1ccc(NC(=O)NS(=O)(=O)c2ccc(F)s2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.40
CA12 O43570 6/20 0.38
CA9 Q16790 6/20 0.38
CA1 P00915 5/20 0.38
CA2 P00918 5/20 0.38
DGAT1 O75907 1/20 0.35
FBP1 P09467 3/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CA13 Q8N1Q1 1/20 0.35
CA14 Q9ULX7 1/20 0.35
USP2 O75604 1/20 0.35
PPARG P37231 1/20 0.34
TP53 P04637 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12177621 0.90 P2RY12 (0.46) P2RY12CA12CA9CA1CA2
SCHEMBL12161620 0.89 P2RY12 (0.38) P2RY12CA12CA9CA1CA2
SCHEMBL9922869 0.83 P2RY12 (0.37) P2RY12CA12CA9CA1CA2
SCHEMBL9922872 0.82 P2RY12 (0.38) P2RY12CA12CA9CA1CA2
SCHEMBL12160945 0.79 FBP1 (0.45) P2RY12CA12CA9CA1CA2
SCHEMBL12706582 0.78 P2RY12 (0.46) P2RY12CA12CA9CA1CA2
SCHEMBL14113566 0.77 P2RY12 (0.56) P2RY12CA12CA9CA1FBP1
SCHEMBL9923247 0.77 P2RY12 (0.40) P2RY12CA12CA9CA1CA2
SCHEMBL9922734 0.77 ALDH1A1 (0.48) P2RY12FBP1KMT2APPARGTP53
SCHEMBL9922587 0.77 P2RY12 (0.54) P2RY12CA12CA9CA1FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885CA12 4616/4885CA9 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.